Celldex (CLDX) jumps 9.6% after saying its CDX-011 drug delayed tumor growth and extended the...


Celldex (CLDX) jumps 9.6% after saying its CDX-011 drug delayed tumor growth and extended the survival of patients with advanced breast cancer compared with those who received single-agent chemotherapy in a Phase II trial. Seattle Genetics (SGEN) also has an interest in the drug. Celldex now hopes to persuade the FDA to authorize a confirmatory study of CDX-011, which could lead to accelerated approval. (PR)

From other sites
Comments (1)
  • jmarkman
    , contributor
    Comments (2) | Send Message
     
    hope its green by days end, wallstreet does not treat CLDX well!
    10 Dec 2012, 10:07 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs